Applications of Chemical Shift Imaging for AD

Abstract

With the global prevalence of Alzheimer's Disease expected to double in the next twenty years, the importance of early diagnosis and biomarkers for disease progression has never been more important. Magnetic Resonance Spectroscopy (MRS) is becoming an increasingly important tool for measuring pathology, disease progression, and drug treatment effects. 2D and 3D Chemical Shift Imaging (CSI) is a burgeoning technique that may play an even more key role as technology advances, allowing for faster and more accurate acquisition while acquiring more myriad data than conventional single-voxel MRS. Measurement of brain metabolites in vivo, such as N-acetyl-aspartate, choline, creatine, myoinositol, glutamate, and glutamine, allows researchers and clinicians alike to better understand the complex processes and interactions that are occurring in the brain from normal ageing, through mild cognitive impairment to dementia and Alzheimer's Disease. This review examines the current state of 2D/3D CSI research on Alzheimer's Disease, including a brief history of spectroscopy, current applications, biological and technical challenges, and highlights of technological advances that will drive future development of the technique.

A review of β-amyloid neuroimaging in Alzheimer's disease

“…The most commonly studied metabolites in MRS experiments of the brains of AD patients are N-acetyl-aspartate (NAA), choline and creatinine, which are associated with neuronal function, membrane turnover and energy consumption respectively (Lee et al, 2003; Coimbra et al, 2006; Scott et al, 2011). NAA has been found to be decreased in AD, consistent with neuronal damage (Coimbra et al, 2006).…”